$NTHIOct 7, 2026, 9:43 AM ETAI processed
NeOnc (NTHI) shows encouraging Phase 2a survival signal for intranasal NEO100; 2026 cancer breakthroughs roundup
AI Summary
NeOnc reported a 24-patient Phase 2a trial of intranasal NEO100 in recurrent high-grade IDH1‑mutant glioma showed a median overall survival of 26.09 months (60.9% at 12 months, 54.1% at 24 months) with predominantly low-grade adverse events, and the company plans to discuss a potential registrational pathway with the FDA. The article positions that finding alongside other 2026 oncology developments ranging from Revolution Medicines’ FDA approval in pancreatic cancer to positive Phase 3 results from Moderna/Merck, J&J and Genmab/AbbVie, emphasizing these represent mixed levels of evidence from exploratory signals to randomized approvals.
Positives
- Phase 2a cohort (n=24) reported median overall survival 26.09 months measured from first treatment after recurrence
- NEO100 is administered intranasally for at‑home dosing and was reported with predominantly low‑grade adverse events and no major toxicities
- Company intends to discuss a registrational development pathway with the FDA (and has other upcoming regulatory meetings)
Negatives
- Small, single‑arm study with no concurrent control group — survival is an encouraging signal but not a randomized proof of benefit
- Progression‑free survival results were inconsistent, meeting significance against a historical benchmark under one assessment method but not under the original protocol criteria
- Article is a paid editorial and discloses the publisher was compensated by NTHI, introducing potential promotional bias